• Xinglong Liang, Li Zhou, and Jun Yan.
• Department of Dermatology, Maoming People's Hospital, Maoming, Guangdong, China. Electronic address: liangxl163@163.com.
• Burns. 2020 May 1; 46 (3): 621-629.

ObjectiveTo evaluate the efficacy and safety of amniotic membrane (AM) for the healing of split-thickness skin graft donor sites (STSGDS).MethodElectronic search of PubMed, Cochrane library and EMBASE for randomized controlled trials (RCTs) or non-randomized clinical trials (NRCTs) of AM therapy in STSGDS. Review Manager5.3 was utilized to analyze and present the data.ResultsSeven studies with 219 patients were included. Compared with other treatments, the mean difference (MD) in healing time was -3.87 days (95% CI -4.39, -3.35; P < 0.00001); Relative risk for the healing rate was 1.61 (95% CI 0.0.47-5.47; P = 0.44); There was no statistical difference in the sensation of pain (P > 0.05); The relative risk for infection rate was 0.66 (95% CI 0.29, 2.18; I2 = 0%; P = 0.65).ConclusionThis systematic review and meta-analysis indicate that it is effective and safe to use AM for treating STSGDS.Copyright © 2019 Elsevier Ltd and ISBI. All rights reserved.

19 keywords...

hide…